Consultant, Division of Circulatory Failure, Department of Cardiovascular Medicine, Mayo Clinic
Professor, Mayo Clinic College of Medicine
University of Ottawa Heart Institute/The Ottawa Hospital-Department of Medicine
Dr. Lisa Mielniczuk completed her medical degree at McMaster University and subsequently went on to complete a residency in Internal Medicine from Queen's University and a Cardiology Fellowship at the University of Ottawa Heart Institute. She also completed a fellowship in advanced heart failure/cardiac transplantation at the Brigham and Women's Hospital in Boston - where she also concurrently completed a Master's Degree in Clinical Science and Epidemiology at the Harvard School of Public Health. Dr. Mielniczuk is currently an Professor of Medicine at the University of Ottawa and the Director of the Advanced Heart Diseases Program at the Ottawa Heart Institute. She is also cross-appointed to the Department of Cellular and Molecular Medicine. Her commitment to leadership and program development is evident in her multiple accomplishments at the Heart Institute, including being the co-Founder and Director of the Pulmonary Hypertension Program, developing a Rapid Intervention Clinic for HF patients, and a Regional HF program for the Ottawa/Champlain region. She is a translational scientist and currently holds a University of Ottawa Chair in Heart Function Research, has more than 100 peer reviewed papers, and has built a multi-disciplinary right heart failure research program at the University of Ottawa. Provincially and Nationally, Dr. Mielniczuk is an active leader for the HF and Pulmonary Hypertension community and serving as the Vice-Chair on the Pulmonary Hypertension Association of Canada. Dr. Mielniczuk is a member of the CorHealth Ontario Senior Leadership Council for Cardiac Disease, as well as an expert panel member for CADTH and Health Quality Ontario. She has been a Canadian Cardiovascular Society Council member since 2015 and is currently serving as the Secretary and treasurer for the Executive. In 2019 Dr. Mielniczuk was appointed Vice-Chair of Patient Safety and Clinical Care for the Department of Medicine at the University of Ottawa.
Disclosure(s): Astra Zeneca: Ad Boards (Ongoing), speaker fees (Ongoing); GSK: ad boards (Ongoing), speaker fees (Ongoing); Janssen: ad boards (Ongoing), speaker fees (Ongoing); Merck: ad boards (Ongoing); Servier: speaker fees (Terminated, January 1, 2023)
203 - ADVANCES IN PULMONARY HYPERTENSION – ENHANCING CARE THROUGH INNOVATION AND COLLABORATION
Friday, October 25, 2024
12:30 PM – 1:30 PM PT
323 - CHFS SPOTLIGHT: WHAT TO DO WHEN PATIENTS FALL OUTSIDE OF CLINICAL TRIALS' INCLUSION CRITERIA?
Saturday, October 26, 2024
9:45 AM – 10:45 AM PT